Company intelligence / Profile preview
Neuraxpharm
Multiple European countriesneuraxpharm.com ↗
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Other
01
Overview
Neuraxpharm is a European leader in pharmaceuticals for CNS disorders with a portfolio of more than 120 molecules covering various treatment options
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesoral solid dosage formssterile formsorodispersible tablets
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Partners from around the globe, specific names not provided
Beyond the preview
Go deeper on Neuraxpharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuraxpharm.